Together, these results suggest that the combination of GB13 and GV24 points in the TNEA therapy may synergistically reduce the APP/CTFs levels via autophagic degradation [28] and other unknown mechanisms, thus leading to the attenuation of memory impairment in 5xFAD mice. The gene discussed is APP; the disease is memory impairment.